Skip to content

Role of Homoeopathy in the treatment of Type 2 Diabetes

Effectiveness of add-on Homoeopathy in treatment of Type 2 Diabetes with or without complications: A multicentric pragmatic double-blind randomized controlled trial - DM-RCT

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058499
Enrollment
330
Registered
2023-10-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E11- Type 2 diabetes mellitus

Interventions

Intervention1: Individualized Homoeopathy with standard Of Care: Group 2: All participants will be given individualized homoeopathic medicine in LM potency customized to each participant, which starts

Sponsors

Central Council for Research in Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Age 30 years and 60 years 2)Known diabetic participants with HbA1c more than equal to 7% and on OHA/insulin 3)Participants with type 2 diabetes mellitus with or without complications 4)Able to comply with the study protocol 5)Voluntary written informed consent

Exclusion criteria

Exclusion criteria: 1)Pregnant ladies and breastfeeding mothers 2)Known cases of HIV, Chronic kidney disease on dialysis and cancer 3)Severe complications in the past six months include myocardial infarction, stroke, severe traumatic injury, major surgery. Other diseases evaluated by the investigator that are not suitable for the project 4)Likely to move away from the study site in next 01 year after.

Design outcomes

Primary

MeasureTime frame
Proportion of participants having HbA1c less than 7% over 12 monthsTimepoint: over 12 months

Secondary

MeasureTime frame
Fasting blood glucoseTimepoint: Baseline and every month till month 12;Adverse effects during the study periodTimepoint: Throughout the study;IL-6 ,CRP levelsTimepoint: Month 6 and 12;Post-prandial blood glucoseTimepoint: Baseline, Month 3,6,9,12;Proportion of participants having a reduction in dosage/withdrawal of OHA/insulinTimepoint: Over 12 months;Proportion of participants withdrawn/tapered of OHA /insulinTimepoint: over 12 months;Quality of life through TRIM-DTimepoint: Baseline, month 3,6,9,12;Symptoms through DSC-RTimepoint: Baseline, month 3,6,9,12;Telomerase activity and telomere lengthTimepoint: Baseline and month 12;Time to remission of HbA1cTimepoint: Month 3,6,9 and 12

Countries

India

Contacts

Public ContactDr Debadatta Nayak

Central Council for Research in Homoeopathy

varanasiroja@gmail.com9999454036

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026